Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | 48.86% | 15.30% | 3,344.63% | -24.39% | |
| Total Depreciation and Amortization | 131.21% | 150.00% | 61.90% | 22.03% | |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | -14.42% | -- | |
| Total Other Non-Cash Items | -49.85% | -50.36% | -25,647.47% | 7.60% | |
| Change in Net Operating Assets | -99.99% | 185.28% | 526.22% | -57.41% | |
| Cash from Operations | 23.06% | 44.18% | -44.82% | -49.65% | |
| Capital Expenditure | 99.54% | 69.54% | -283.28% | -4,765.22% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | 99.54% | 69.54% | -283.28% | -4,765.22% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -100.00% | -100.00% | 5,823.80% | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -53.67% | 53.67% | |
| Cash from Financing | -100.00% | -100.00% | 217.45% | 53.67% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 26.37% | -121.08% | 37.25% | -- | |
